Breaking: Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices

It's Sanders' latest move to pressure Novo to cut the prices of the blockbuster diabetes and obesity therapies

Log In    Subscribe BREAKING NEWS   Sanders says PBMs won't penalize Novo for cutting Ozempic, Wegovy prices By Rachel Cohrs Zhang and Elaine Chen Kevin Dietsch/Getty Images In a Senate health committee hearing today, Sen. Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk's Ozempic and Wegovy if the company lowers the prices of the treatments. It's Sanders' latest move to pressure Novo to cut the prices of the blockbuster diabetes and obesity therapies. READ MORE Sign up for D.C. Diagnosis Your essential briefing on health care politics and policy. Learn more. In Case You Missed It 1   Bernie Sanders may have reached the limits of his pharma pressure campaign Rachel Cohrs Zhang 2   Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target By Elaine Chen and Allison DeAngelis 3   The U.S. has relied on cheap, effective generic drugs for 40 years. Now that promise is under threat By Leslie Walker and Dan Gorenstein 4   Electronic health records giant Epic Systems sued over alleged monopolistic practices By Casey Ross Don't miss out on another STAT Investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us